The American Journal of Medicine
Volume 120, Issue 3 , Pages 251-256 , March 2007

Gaps in Treatment Among Users of Osteoporosis Medications: The Dynamics of Noncompliance

References 

  1. Haynes RB, Taylor WD, Sackett DL. Compliance in Health Care. Baltimore, MD: The Johns Hopkins University Press; 1979;
  2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497
  3. Hughes DA, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. 2001;10:601–615
  4. Stephenson J. Noncompliance may cause half of antihypertensive drug “failures”. JAMA. 1999;282:313–314
  5. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. [see comment] [erratum appears in JAMA. 2003 Jun 25;289:3242] JAMA. 2002;288:2868–2879
  6. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications [update of Cochrane Database Syst Rev. 2000(2):CD000011; PMID: 10796686]. Cochrane Database Syst Rev. 2002(2):CD000011.
  7. Sabate E. Adherence to long-term therapies: evidence for action. World Health Organization [Web report]. 2005;Available at: http://www.who.int/chronic_conditions/en/adherence_report.pdf. Accessed August 10
  8. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414–2419
  9. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:1117–1123
  10. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19:638–645
  11. Yang CC, Jick SS, Testa MA. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics. Br J Clin Pharmacol. 2003;56:84–91
  12. Grant RW, O’Leary KM, Weilburg JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004;164:2343–2348
  13. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients [see comment]. JAMA. 2002;288:455–461
  14. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147–1152
  15. Urquhart J. Erratic patient compliance with prescribed drug regimens: target for drug delivery systems. Clin Pharmacol Ther. 2000;67:331–334
  16. Urquhart J. The electronic medication event monitor (Lessons for pharmacotherapy). Clin Pharmacokinet. 1997;32:345–356
  17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  18. Cox DR. Regression models and lifetables. J R Stat Soc Ser B. 1972;187–220
  19. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133:144–153
  20. Wang PS, Schneeweiss S, Glynn RJ, Mogun H, Avorn J. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol. 2004;14:296–303
  21. SAS, Version 9.1 [computer program]. Cary, NC: SAS Institute Inc.; 2003.
  22. Jachna CM, Shireman TI, Whittle J, Ellerbeck EF, Rigler SK. Differing patterns of antiresorptive pharmacotherapy in nursing facility residents and community dwellers. J Am Geriatr Soc. 2005;53:1275–1281
  23. Gupta G, Aronow WS. Underuse of procedures for diagnosing osteoporosis and of therapies for osteoporosis in older nursing home residents. J Am Med Dir Assoc. 2003;4:200–202

 Supported by the National Institutes of Health (AR-48616, DK-02759, AR-47782, and AG-027400). Investigators are also supported by grants from the Arthritis Foundation and the Engalitcheff Arthritis Outcomes Initiative. There was no pharmaceutical industry support for this study.

PII: S0002-9343(06)00506-7

doi: 10.1016/j.amjmed.2006.03.029

The American Journal of Medicine
Volume 120, Issue 3 , Pages 251-256 , March 2007

Article Tools

* Image Usage & Resolution